Carlsmed, Inc. (CARL) Stock Competitors & Peer Comparison
See (CARL) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CARL | $11.90 | -2.54% | 323.5M | -4.74 | -$2.51 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $93.93 | -0.50% | 163.6B | 18.02 | $5.21 | +2.59% |
| ISRG | $406.78 | -1.16% | 144.1B | 42.28 | $9.62 | N/A |
| SYK | $329.78 | +0.82% | 126.4B | 24.63 | $13.39 | +1.05% |
| MDT | $83.87 | +1.80% | 107.3B | 15.16 | $5.53 | +3.40% |
| BSX | $44.77 | -0.49% | 66.5B | 14.44 | $3.10 | N/A |
| EW | $92.21 | +0.96% | 53.1B | 34.15 | $2.70 | N/A |
| RMD | $203.87 | -2.20% | 29.6B | 18.93 | $10.77 | +1.17% |
| DXCM | $74.96 | +2.66% | 28.9B | 32.17 | $2.33 | N/A |
Stock Comparison
CARL vs BSX-PA Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, CARL is priced at $11.90, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, CARL's ROE is -0.62%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, CARL is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check BSX-PA's competition here
CARL vs ABT Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, ABT has a market cap of 163.6B. Regarding current trading prices, CARL is priced at $11.90, while ABT trades at $93.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas ABT's P/E ratio is 18.02. In terms of profitability, CARL's ROE is -0.62%, compared to ABT's ROE of +0.12%. Regarding short-term risk, CARL is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check ABT's competition here
CARL vs ISRG Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, ISRG has a market cap of 144.1B. Regarding current trading prices, CARL is priced at $11.90, while ISRG trades at $406.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas ISRG's P/E ratio is 42.28. In terms of profitability, CARL's ROE is -0.62%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, CARL is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check ISRG's competition here
CARL vs SYK Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, SYK has a market cap of 126.4B. Regarding current trading prices, CARL is priced at $11.90, while SYK trades at $329.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas SYK's P/E ratio is 24.63. In terms of profitability, CARL's ROE is -0.62%, compared to SYK's ROE of +0.15%. Regarding short-term risk, CARL is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check SYK's competition here
CARL vs MDT Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, MDT has a market cap of 107.3B. Regarding current trading prices, CARL is priced at $11.90, while MDT trades at $83.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas MDT's P/E ratio is 15.16. In terms of profitability, CARL's ROE is -0.62%, compared to MDT's ROE of +0.10%. Regarding short-term risk, CARL is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check MDT's competition here
CARL vs BSX Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, BSX has a market cap of 66.5B. Regarding current trading prices, CARL is priced at $11.90, while BSX trades at $44.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas BSX's P/E ratio is 14.44. In terms of profitability, CARL's ROE is -0.62%, compared to BSX's ROE of +0.15%. Regarding short-term risk, CARL is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check BSX's competition here
CARL vs EW Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, EW has a market cap of 53.1B. Regarding current trading prices, CARL is priced at $11.90, while EW trades at $92.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas EW's P/E ratio is 34.15. In terms of profitability, CARL's ROE is -0.62%, compared to EW's ROE of +0.11%. Regarding short-term risk, CARL is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check EW's competition here
CARL vs RMD Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, RMD has a market cap of 29.6B. Regarding current trading prices, CARL is priced at $11.90, while RMD trades at $203.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas RMD's P/E ratio is 18.93. In terms of profitability, CARL's ROE is -0.62%, compared to RMD's ROE of +0.24%. Regarding short-term risk, CARL is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check RMD's competition here
CARL vs DXCM Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, DXCM has a market cap of 28.9B. Regarding current trading prices, CARL is priced at $11.90, while DXCM trades at $74.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas DXCM's P/E ratio is 32.17. In terms of profitability, CARL's ROE is -0.62%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, CARL is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check DXCM's competition here
CARL vs ZBH Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, ZBH has a market cap of 17.7B. Regarding current trading prices, CARL is priced at $11.90, while ZBH trades at $91.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas ZBH's P/E ratio is 10.77. In terms of profitability, CARL's ROE is -0.62%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, CARL is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check ZBH's competition here
CARL vs ABMD Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, CARL is priced at $11.90, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas ABMD's P/E ratio is 65.36. In terms of profitability, CARL's ROE is -0.62%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, CARL is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check ABMD's competition here
CARL vs SNN Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, SNN has a market cap of 13B. Regarding current trading prices, CARL is priced at $11.90, while SNN trades at $30.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas SNN's P/E ratio is 16.58. In terms of profitability, CARL's ROE is -0.62%, compared to SNN's ROE of +0.12%. Regarding short-term risk, CARL is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check SNN's competition here
CARL vs ALGN Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, ALGN has a market cap of 12.9B. Regarding current trading prices, CARL is priced at $11.90, while ALGN trades at $179.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas ALGN's P/E ratio is 16.36. In terms of profitability, CARL's ROE is -0.62%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, CARL is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check ALGN's competition here
CARL vs SWAV Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, CARL is priced at $11.90, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas SWAV's P/E ratio is 78.76. In terms of profitability, CARL's ROE is -0.62%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, CARL is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check SWAV's competition here
CARL vs PEN Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, CARL is priced at $11.90, while PEN trades at $318.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas PEN's P/E ratio is 83.05. In terms of profitability, CARL's ROE is -0.62%, compared to PEN's ROE of +0.12%. Regarding short-term risk, CARL is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check PEN's competition here
CARL vs PODD Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, PODD has a market cap of 11.2B. Regarding current trading prices, CARL is priced at $11.90, while PODD trades at $161.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas PODD's P/E ratio is 29.98. In terms of profitability, CARL's ROE is -0.62%, compared to PODD's ROE of +0.21%. Regarding short-term risk, CARL is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check PODD's competition here
CARL vs GMED Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, GMED has a market cap of 10.5B. Regarding current trading prices, CARL is priced at $11.90, while GMED trades at $78.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas GMED's P/E ratio is 17.59. In terms of profitability, CARL's ROE is -0.62%, compared to GMED's ROE of +0.13%. Regarding short-term risk, CARL is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check GMED's competition here
CARL vs MASI Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, CARL is priced at $11.90, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas MASI's P/E ratio is 44.43. In terms of profitability, CARL's ROE is -0.62%, compared to MASI's ROE of +0.09%. Regarding short-term risk, CARL is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check MASI's competition here
CARL vs BRKR Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, CARL is priced at $11.90, while BRKR trades at $60.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas BRKR's P/E ratio is 33.00. In terms of profitability, CARL's ROE is -0.62%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, CARL is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check BRKR's competition here
CARL vs GKOS Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, GKOS has a market cap of 9B. Regarding current trading prices, CARL is priced at $11.90, while GKOS trades at $152.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas GKOS's P/E ratio is -177.62. In terms of profitability, CARL's ROE is -0.62%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, CARL is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check GKOS's competition here
CARL vs BIO-B Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, BIO-B has a market cap of 8.2B. Regarding current trading prices, CARL is priced at $11.90, while BIO-B trades at $298.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas BIO-B's P/E ratio is 88.55. In terms of profitability, CARL's ROE is -0.62%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, CARL is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check BIO-B's competition here
CARL vs BIO Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, BIO has a market cap of 8B. Regarding current trading prices, CARL is priced at $11.90, while BIO trades at $296.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas BIO's P/E ratio is 31.95. In terms of profitability, CARL's ROE is -0.62%, compared to BIO's ROE of +0.02%. Regarding short-term risk, CARL is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check BIO's competition here
CARL vs NARI Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, CARL is priced at $11.90, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas NARI's P/E ratio is -59.24. In terms of profitability, CARL's ROE is -0.62%, compared to NARI's ROE of -0.00%. Regarding short-term risk, CARL is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check NARI's competition here
CARL vs LIVN Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, LIVN has a market cap of 4.5B. Regarding current trading prices, CARL is priced at $11.90, while LIVN trades at $82.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas LIVN's P/E ratio is 20.63. In terms of profitability, CARL's ROE is -0.62%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, CARL is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check LIVN's competition here
CARL vs IRTC Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, CARL is priced at $11.90, while IRTC trades at $116.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas IRTC's P/E ratio is -207.37. In terms of profitability, CARL's ROE is -0.62%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, CARL is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check IRTC's competition here
CARL vs AXNX Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, CARL is priced at $11.90, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas AXNX's P/E ratio is -709.80. In terms of profitability, CARL's ROE is -0.62%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, CARL is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check AXNX's competition here
CARL vs ITGR Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, ITGR has a market cap of 3.2B. Regarding current trading prices, CARL is priced at $11.90, while ITGR trades at $93.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas ITGR's P/E ratio is 14.86. In terms of profitability, CARL's ROE is -0.62%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, CARL is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check ITGR's competition here
CARL vs ESTA Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, ESTA has a market cap of 2.6B. Regarding current trading prices, CARL is priced at $11.90, while ESTA trades at $88.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas ESTA's P/E ratio is -61.13. In terms of profitability, CARL's ROE is -0.62%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, CARL is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check ESTA's competition here
CARL vs TMDX Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, CARL is priced at $11.90, while TMDX trades at $71.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas TMDX's P/E ratio is 29.07. In terms of profitability, CARL's ROE is -0.62%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, CARL is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check TMDX's competition here
CARL vs AXGN Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, CARL is priced at $11.90, while AXGN trades at $40.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas AXGN's P/E ratio is 106.79. In terms of profitability, CARL's ROE is -0.62%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, CARL is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check AXGN's competition here
CARL vs BFLY Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, BFLY has a market cap of 2.1B. Regarding current trading prices, CARL is priced at $11.90, while BFLY trades at $7.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas BFLY's P/E ratio is -33.23. In terms of profitability, CARL's ROE is -0.62%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, CARL is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check BFLY's competition here
CARL vs NUVA Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, CARL is priced at $11.90, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas NUVA's P/E ratio is 75.00. In terms of profitability, CARL's ROE is -0.62%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, CARL is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check NUVA's competition here
CARL vs NVCR Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, CARL is priced at $11.90, while NVCR trades at $16.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas NVCR's P/E ratio is -10.65. In terms of profitability, CARL's ROE is -0.62%, compared to NVCR's ROE of -0.51%. Regarding short-term risk, CARL is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check NVCR's competition here
CARL vs UFPT Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, CARL is priced at $11.90, while UFPT trades at $236.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas UFPT's P/E ratio is 24.15. In terms of profitability, CARL's ROE is -0.62%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, CARL is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check UFPT's competition here
CARL vs INSP Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, INSP has a market cap of 1.5B. Regarding current trading prices, CARL is priced at $11.90, while INSP trades at $51.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas INSP's P/E ratio is 20.06. In terms of profitability, CARL's ROE is -0.62%, compared to INSP's ROE of +0.18%. Regarding short-term risk, CARL is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check INSP's competition here
CARL vs ENOV Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, CARL is priced at $11.90, while ENOV trades at $25.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas ENOV's P/E ratio is 7.62. In terms of profitability, CARL's ROE is -0.62%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, CARL is more volatile compared to ENOV. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check ENOV's competition here
CARL vs ATEC Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, CARL is priced at $11.90, while ATEC trades at $9.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas ATEC's P/E ratio is -87.09. In terms of profitability, CARL's ROE is -0.62%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, CARL is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check ATEC's competition here
CARL vs IART Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, IART has a market cap of 1.5B. Regarding current trading prices, CARL is priced at $11.90, while IART trades at $18.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas IART's P/E ratio is 7.96. In terms of profitability, CARL's ROE is -0.62%, compared to IART's ROE of -0.48%. Regarding short-term risk, CARL is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check IART's competition here
CARL vs AHCO Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, CARL is priced at $11.90, while AHCO trades at $10.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas AHCO's P/E ratio is 23.23. In terms of profitability, CARL's ROE is -0.62%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, CARL is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check AHCO's competition here
CARL vs HSKA Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, CARL is priced at $11.90, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas HSKA's P/E ratio is -62.49. In terms of profitability, CARL's ROE is -0.62%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, CARL is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check HSKA's competition here
CARL vs IRMD Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, CARL is priced at $11.90, while IRMD trades at $97.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas IRMD's P/E ratio is 48.84. In terms of profitability, CARL's ROE is -0.62%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, CARL is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check IRMD's competition here
CARL vs PRCT Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, CARL is priced at $11.90, while PRCT trades at $20.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas PRCT's P/E ratio is -11.48. In terms of profitability, CARL's ROE is -0.62%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, CARL is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check PRCT's competition here
CARL vs LMRI Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, LMRI has a market cap of 1.2B. Regarding current trading prices, CARL is priced at $11.90, while LMRI trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas LMRI's P/E ratio is -23.70. In terms of profitability, CARL's ROE is -0.62%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, CARL is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check LMRI's competition here
CARL vs AORT Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, CARL is priced at $11.90, while AORT trades at $24.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas AORT's P/E ratio is 37.04. In terms of profitability, CARL's ROE is -0.62%, compared to AORT's ROE of +0.03%. Regarding short-term risk, CARL is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check AORT's competition here
CARL vs AVNS Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, CARL is priced at $11.90, while AVNS trades at $24.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas AVNS's P/E ratio is 27.71. In terms of profitability, CARL's ROE is -0.62%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, CARL is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check AVNS's competition here
CARL vs CNMD Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, CNMD has a market cap of 1.2B. Regarding current trading prices, CARL is priced at $11.90, while CNMD trades at $38.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas CNMD's P/E ratio is 8.46. In terms of profitability, CARL's ROE is -0.62%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, CARL is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check CNMD's competition here
CARL vs SILK Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, CARL is priced at $11.90, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas SILK's P/E ratio is -18.96. In terms of profitability, CARL's ROE is -0.62%, compared to SILK's ROE of -0.35%. Regarding short-term risk, CARL is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check SILK's competition here
CARL vs FNA Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, CARL is priced at $11.90, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas FNA's P/E ratio is -19.83. In terms of profitability, CARL's ROE is -0.62%, compared to FNA's ROE of -0.35%. Regarding short-term risk, CARL is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check FNA's competition here
CARL vs TNDM Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, CARL is priced at $11.90, while TNDM trades at $15.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas TNDM's P/E ratio is -14.01. In terms of profitability, CARL's ROE is -0.62%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, CARL is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check TNDM's competition here
CARL vs INMD Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, INMD has a market cap of 878.3M. Regarding current trading prices, CARL is priced at $11.90, while INMD trades at $15.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas INMD's P/E ratio is 9.79. In terms of profitability, CARL's ROE is -0.62%, compared to INMD's ROE of +0.13%. Regarding short-term risk, CARL is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check INMD's competition here
CARL vs CSII Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, CARL is priced at $11.90, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas CSII's P/E ratio is -20.83. In terms of profitability, CARL's ROE is -0.62%, compared to CSII's ROE of -0.14%. Regarding short-term risk, CARL is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check CSII's competition here
CARL vs BVS Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, BVS has a market cap of 804.8M. Regarding current trading prices, CARL is priced at $11.90, while BVS trades at $11.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas BVS's P/E ratio is 15.84. In terms of profitability, CARL's ROE is -0.62%, compared to BVS's ROE of +0.16%. Regarding short-term risk, CARL is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check BVS's competition here
CARL vs SIBN Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, SIBN has a market cap of 778.8M. Regarding current trading prices, CARL is priced at $11.90, while SIBN trades at $17.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas SIBN's P/E ratio is -45.03. In terms of profitability, CARL's ROE is -0.62%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, CARL is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check SIBN's competition here
CARL vs SSII Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, SSII has a market cap of 758.5M. Regarding current trading prices, CARL is priced at $11.90, while SSII trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas SSII's P/E ratio is -73.92. In terms of profitability, CARL's ROE is -0.62%, compared to SSII's ROE of -0.23%. Regarding short-term risk, CARL is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check SSII's competition here
CARL vs CBLL Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, CBLL has a market cap of 742.2M. Regarding current trading prices, CARL is priced at $11.90, while CBLL trades at $19.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas CBLL's P/E ratio is -12.00. In terms of profitability, CARL's ROE is -0.62%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, CARL is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check CBLL's competition here
CARL vs TCMD Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, TCMD has a market cap of 672.9M. Regarding current trading prices, CARL is priced at $11.90, while TCMD trades at $29.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas TCMD's P/E ratio is 33.90. In terms of profitability, CARL's ROE is -0.62%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, CARL is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check TCMD's competition here
CARL vs CERS Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, CERS has a market cap of 625.2M. Regarding current trading prices, CARL is priced at $11.90, while CERS trades at $3.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas CERS's P/E ratio is -62.28. In terms of profitability, CARL's ROE is -0.62%, compared to CERS's ROE of -0.15%. Regarding short-term risk, CARL is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check CERS's competition here
CARL vs SRDX Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, CARL is priced at $11.90, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas SRDX's P/E ratio is -34.66. In terms of profitability, CARL's ROE is -0.62%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, CARL is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check SRDX's competition here
CARL vs CTKB Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, CTKB has a market cap of 596.6M. Regarding current trading prices, CARL is priced at $11.90, while CTKB trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas CTKB's P/E ratio is -35.54. In terms of profitability, CARL's ROE is -0.62%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, CARL is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check CTKB's competition here
CARL vs BWAY Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, BWAY has a market cap of 590.7M. Regarding current trading prices, CARL is priced at $11.90, while BWAY trades at $15.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas BWAY's P/E ratio is 38.26. In terms of profitability, CARL's ROE is -0.62%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, CARL is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check BWAY's competition here
CARL vs NPCE Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, NPCE has a market cap of 583.3M. Regarding current trading prices, CARL is priced at $11.90, while NPCE trades at $17.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas NPCE's P/E ratio is -29.50. In terms of profitability, CARL's ROE is -0.62%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, CARL is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check NPCE's competition here
CARL vs APEN Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, CARL is priced at $11.90, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas APEN's P/E ratio is -9.43. In terms of profitability, CARL's ROE is -0.62%, compared to APEN's ROE of -0.85%. Regarding short-term risk, CARL is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check APEN's competition here
CARL vs ZIMV Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, CARL is priced at $11.90, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, CARL's ROE is -0.62%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, CARL is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check ZIMV's competition here
CARL vs CLPT Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, CLPT has a market cap of 524.8M. Regarding current trading prices, CARL is priced at $11.90, while CLPT trades at $17.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas CLPT's P/E ratio is -17.33. In terms of profitability, CARL's ROE is -0.62%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, CARL is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check CLPT's competition here
CARL vs KIDS Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, KIDS has a market cap of 522.2M. Regarding current trading prices, CARL is priced at $11.90, while KIDS trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas KIDS's P/E ratio is -19.74. In terms of profitability, CARL's ROE is -0.62%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, CARL is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check KIDS's competition here
CARL vs PACB Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, PACB has a market cap of 484.5M. Regarding current trading prices, CARL is priced at $11.90, while PACB trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas PACB's P/E ratio is -3.18. In terms of profitability, CARL's ROE is -0.62%, compared to PACB's ROE of -4.88%. Regarding short-term risk, CARL is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check PACB's competition here
CARL vs OFIX Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, OFIX has a market cap of 470.1M. Regarding current trading prices, CARL is priced at $11.90, while OFIX trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas OFIX's P/E ratio is -47.37. In terms of profitability, CARL's ROE is -0.62%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, CARL is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check OFIX's competition here
CARL vs VREX Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, VREX has a market cap of 465.2M. Regarding current trading prices, CARL is priced at $11.90, while VREX trades at $11.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas VREX's P/E ratio is 11.63. In terms of profitability, CARL's ROE is -0.62%, compared to VREX's ROE of -0.18%. Regarding short-term risk, CARL is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check VREX's competition here
CARL vs DCTH Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, DCTH has a market cap of 449.1M. Regarding current trading prices, CARL is priced at $11.90, while DCTH trades at $13.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas DCTH's P/E ratio is 1301.00. In terms of profitability, CARL's ROE is -0.62%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, CARL is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check DCTH's competition here
CARL vs ELMD Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, ELMD has a market cap of 379.5M. Regarding current trading prices, CARL is priced at $11.90, while ELMD trades at $45.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas ELMD's P/E ratio is 39.17. In terms of profitability, CARL's ROE is -0.62%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, CARL is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check ELMD's competition here
CARL vs AVR Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, AVR has a market cap of 359.4M. Regarding current trading prices, CARL is priced at $11.90, while AVR trades at $9.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas AVR's P/E ratio is -4.38. In terms of profitability, CARL's ROE is -0.62%, compared to AVR's ROE of -1.24%. Regarding short-term risk, CARL is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check AVR's competition here
CARL vs SMLR Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, CARL is priced at $11.90, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas SMLR's P/E ratio is 3.92. In terms of profitability, CARL's ROE is -0.62%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, CARL is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check SMLR's competition here
CARL vs SGHT Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, SGHT has a market cap of 289.5M. Regarding current trading prices, CARL is priced at $11.90, while SGHT trades at $5.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas SGHT's P/E ratio is -8.44. In terms of profitability, CARL's ROE is -0.62%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, CARL is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check SGHT's competition here
CARL vs TMCI Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, TMCI has a market cap of 280.3M. Regarding current trading prices, CARL is priced at $11.90, while TMCI trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas TMCI's P/E ratio is -4.60. In terms of profitability, CARL's ROE is -0.62%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, CARL is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check TMCI's competition here
CARL vs MGRM Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, CARL is priced at $11.90, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas MGRM's P/E ratio is -12.00. In terms of profitability, CARL's ROE is -0.62%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, CARL is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check MGRM's competition here
CARL vs PMI Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, PMI has a market cap of 240.7M. Regarding current trading prices, CARL is priced at $11.90, while PMI trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas PMI's P/E ratio is -0.13. In terms of profitability, CARL's ROE is -0.62%, compared to PMI's ROE of +4.99%. Regarding short-term risk, CARL is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check PMI's competition here
CARL vs CATX Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, CATX has a market cap of 231.8M. Regarding current trading prices, CARL is priced at $11.90, while CATX trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas CATX's P/E ratio is -2.13. In terms of profitability, CARL's ROE is -0.62%, compared to CATX's ROE of -0.42%. Regarding short-term risk, CARL is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check CATX's competition here
CARL vs SENS Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, SENS has a market cap of 224.9M. Regarding current trading prices, CARL is priced at $11.90, while SENS trades at $5.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas SENS's P/E ratio is -2.69. In terms of profitability, CARL's ROE is -0.62%, compared to SENS's ROE of -1.30%. Regarding short-term risk, CARL is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check SENS's competition here
CARL vs NVRO Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, CARL is priced at $11.90, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas NVRO's P/E ratio is -1.91. In terms of profitability, CARL's ROE is -0.62%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, CARL is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check NVRO's competition here
CARL vs PROF Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, PROF has a market cap of 219.7M. Regarding current trading prices, CARL is priced at $11.90, while PROF trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas PROF's P/E ratio is -5.85. In terms of profitability, CARL's ROE is -0.62%, compared to PROF's ROE of -0.70%. Regarding short-term risk, CARL is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check PROF's competition here
CARL vs ANIK Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, ANIK has a market cap of 207.6M. Regarding current trading prices, CARL is priced at $11.90, while ANIK trades at $15.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas ANIK's P/E ratio is 31.84. In terms of profitability, CARL's ROE is -0.62%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, CARL is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check ANIK's competition here
CARL vs RXST Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, RXST has a market cap of 204.9M. Regarding current trading prices, CARL is priced at $11.90, while RXST trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas RXST's P/E ratio is -6.88. In terms of profitability, CARL's ROE is -0.62%, compared to RXST's ROE of -0.17%. Regarding short-term risk, CARL is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check RXST's competition here
CARL vs FOCL Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, FOCL has a market cap of 203.7M. Regarding current trading prices, CARL is priced at $11.90, while FOCL trades at $5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas FOCL's P/E ratio is -6.99. In terms of profitability, CARL's ROE is -0.62%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, CARL is more volatile compared to FOCL. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check FOCL's competition here
CARL vs BSGM Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, CARL is priced at $11.90, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas BSGM's P/E ratio is -5.81. In terms of profitability, CARL's ROE is -0.62%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, CARL is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check BSGM's competition here
CARL vs QTRX Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, QTRX has a market cap of 182.8M. Regarding current trading prices, CARL is priced at $11.90, while QTRX trades at $3.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas QTRX's P/E ratio is -2.42. In terms of profitability, CARL's ROE is -0.62%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, CARL is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check QTRX's competition here
CARL vs MDGS Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, CARL is priced at $11.90, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas MDGS's P/E ratio is -0.27. In terms of profitability, CARL's ROE is -0.62%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, CARL is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check MDGS's competition here
CARL vs INGN Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, INGN has a market cap of 177.1M. Regarding current trading prices, CARL is priced at $11.90, while INGN trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas INGN's P/E ratio is -7.19. In terms of profitability, CARL's ROE is -0.62%, compared to INGN's ROE of -0.13%. Regarding short-term risk, CARL is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check INGN's competition here
CARL vs QIPT Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, CARL is priced at $11.90, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas QIPT's P/E ratio is -15.87. In terms of profitability, CARL's ROE is -0.62%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, CARL is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check QIPT's competition here
CARL vs TLSI Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, TLSI has a market cap of 156.9M. Regarding current trading prices, CARL is priced at $11.90, while TLSI trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas TLSI's P/E ratio is -2.46. In terms of profitability, CARL's ROE is -0.62%, compared to TLSI's ROE of +1.63%. Regarding short-term risk, CARL is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check TLSI's competition here
CARL vs CVRX Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, CVRX has a market cap of 144.1M. Regarding current trading prices, CARL is priced at $11.90, while CVRX trades at $5.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas CVRX's P/E ratio is -2.69. In terms of profitability, CARL's ROE is -0.62%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, CARL is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check CVRX's competition here
CARL vs OWLT Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, OWLT has a market cap of 110M. Regarding current trading prices, CARL is priced at $11.90, while OWLT trades at $6.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas OWLT's P/E ratio is -43.43. In terms of profitability, CARL's ROE is -0.62%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, CARL is more volatile compared to OWLT. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check OWLT's competition here
CARL vs ICAD Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, CARL is priced at $11.90, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas ICAD's P/E ratio is -20.37. In terms of profitability, CARL's ROE is -0.62%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, CARL is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check ICAD's competition here
CARL vs HSDT Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, HSDT has a market cap of 102.2M. Regarding current trading prices, CARL is priced at $11.90, while HSDT trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas HSDT's P/E ratio is -0.02. In terms of profitability, CARL's ROE is -0.62%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, CARL is less volatile compared to HSDT. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check HSDT's competition here
CARL vs LUCD Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, LUCD has a market cap of 101.3M. Regarding current trading prices, CARL is priced at $11.90, while LUCD trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas LUCD's P/E ratio is -2.68. In terms of profitability, CARL's ROE is -0.62%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, CARL is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check LUCD's competition here
CARL vs RCEL Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, RCEL has a market cap of 100.9M. Regarding current trading prices, CARL is priced at $11.90, while RCEL trades at $4.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas RCEL's P/E ratio is -2.59. In terms of profitability, CARL's ROE is -0.62%, compared to RCEL's ROE of +3.05%. Regarding short-term risk, CARL is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check RCEL's competition here
CARL vs QTI Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, QTI has a market cap of 99.6M. Regarding current trading prices, CARL is priced at $11.90, while QTI trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas QTI's P/E ratio is -5.40. In terms of profitability, CARL's ROE is -0.62%, compared to QTI's ROE of -63.31%. Regarding short-term risk, CARL is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check QTI's competition here
CARL vs HJLI Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, CARL is priced at $11.90, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas HJLI's P/E ratio is N/A. In terms of profitability, CARL's ROE is -0.62%, compared to HJLI's ROE of -0.66%. Regarding short-term risk, CARL is more volatile compared to HJLI. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check HJLI's competition here
CARL vs ASXC Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, CARL is priced at $11.90, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas ASXC's P/E ratio is -1.12. In terms of profitability, CARL's ROE is -0.62%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, CARL is more volatile compared to ASXC. This indicates potentially higher risk in terms of short-term price fluctuations for CARL.Check ASXC's competition here
CARL vs RPID Comparison July 2026
CARL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CARL stands at 323.5M. In comparison, RPID has a market cap of 92.9M. Regarding current trading prices, CARL is priced at $11.90, while RPID trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CARL currently has a P/E ratio of -4.74, whereas RPID's P/E ratio is -1.83. In terms of profitability, CARL's ROE is -0.62%, compared to RPID's ROE of -1.32%. Regarding short-term risk, CARL is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for CARL.Check RPID's competition here